Neutrophil-to-Lymphocyte Ratio May Guide the Choice of Treatment in Metastatic Cancer Patients: Chemotherapy or Best Supportive Care

Serdar ARICI; Ruhper ÇEKİN

doi:https://doi.org/10.25000/acem.803359

Makale detayları

Neutrophil-to-Lymphocyte Ratio May Guide the Choice of Treatment in Metastatic Cancer Patients: Chemotherapy or Best Supportive Care

Yazarlar:

Serdar ARICI | Ruhper ÇEKİN

Yayıncı:

Mustafa HASBAHÇECİ

Ana Başlıklar:

Hastalıklar

Dergi:

Archives of Clinical and Experimental Medicine 2020 Vol.5 Issue 3, pp.111-115

Belge Tipi:

Makale

Yayın Tarihi:

12/2020

Belge Dili:

İngilizce

Document ID (Org No.):

2000675505

Sıklık:

Üç Yıllık

eISSN:

2564-6567

DOI:

https://doi.org/10.25000/acem.803359

Özet:

 

Aim: We set out in this study to investigate whether the neutrophil-to-lymphocyte ratio (NLR) is a predictor in deciding whether to either continue palliative chemotherapy or choose the best supportive care (BSC) for advanced cancer patients. 
Methods: Those with advanced solid tumors who had died after palliative chemotherapy were included the study. The patients were divided into two groups based on the time between the beginning of their last chemotherapy regimen and death (DCD), at ≤ 60 or > 60 days. Neutrophil-to-lymphocyte ratio was calculated using the laboratory values taken before the beginning of the last chemotherapy line. The determinant factors of ≤ 60-days DCD were examined by logistic regression analysis, and a statistical significance level of alpha was accepted as p < 0.05. 
Results: The study included 404 patients, with the mean age at diagnosis of 61.7±12.0 years. The mean NLR was calculated as 11.3±27.1. In the univariate analysis for determining ≤ 60-days DCD, breast and colorectal cancers, ECOG status, single agent chemotherapy usage, neutrophil count, lymphocyte count and NLR were all found to be significant factors. The cutoff value determining the ≤ 60-days DCD, was determined as NLR ≥ 3.59. In logistic regression analysis, NLR ≥ 3.59, as well as ECOG status, were found to be significant factors. 
Conclusion: The neutrophil-lymphocyte ratio, combined with ECOG, can predict survival in patients with solid advanced tumors and can therefore help clinicians in choosing to either administer chemotherapy to their patients or direct them to the best supportive care.

Makale detayları

Neutrophil-to-Lymphocyte Ratio May Guide the Choice of Treatment in Metastatic Cancer Patients: Chemotherapy or Best Supportive Care

Yazarlar: Serdar ARICI | Ruhper ÇEKİN

Yayıncı: Mustafa HASBAHÇECİ

Ana Başlıklar: Hastalıklar

Dergi: Archives of Clinical and Experimental Medicine 2020 Vol.5 Issue 3, pp.111-115

Belge Tipi: Makale

Yayın Tarihi: 12/2020

Belge Dili: İngilizce

Document ID (Org No.): 2000675505

Sıklık: Üç Yıllık

eISSN: 2564-6567

DOI: https://doi.org/10.25000/acem.803359

Sayı

Yazarlar:

Serdar ARICI | Ruhper ÇEKİN

Yayıncı:

Mustafa HASBAHÇECİ

Ana Başlıklar:

Hastalıklar

Dergi:

Archives of Clinical and Experimental Medicine 2020 Vol.5 Issue 3, pp.111-115

Belge Tipi:

Makale

Yayın Tarihi:

12/2020

Belge Dili:

İngilizce

Document ID (Org No.):

2000675505

Sıklık:

Üç Yıllık

eISSN:

2564-6567

DOI:

https://doi.org/10.25000/acem.803359